A Personal Story Of Loss

Inspiration Behind **Seaside Bio**



Homa, 42 – triple-negative breast cancer with brain metastasis

Received Keytruda **but no PD-L1 expression**

Later testing showed **high TROP2 → Trodelvy was missed**

She passed quickly, leaving behind a 10-year-old daughter



Wrong treatment due to missed target detection - costed a life

Why

Life-Saving Therapies Are Missed

Problem: Non-surgical samples

CSF



FNA



Pediatric Aspirate



low cellularity- often inconclusive

Why it happens

Clinically accessible samples are **poorly served by current tools**

Scale of the problem (underserved samples)

110K leptomeningeal disease	**300K** FNAs
150K malignant pleural effusions	**700K** metastatic cancers annually (US)

Patients miss life-saving therapies because targets go unseen.

Seaside Bio

Revolutionizing Therapy Prediction in Metastatic Cancer



2025 Intro Pitch Deck

CyPhenom™

The Missing Link in Therapy Monitoring

CyPhenom™ transforms non-surgical biopsies into actionable insights, enabling oncologists to match patients with the right therapy, faster.

Sample collection

1



Minimally invasive

works on CSF, pleural, and needle aspirates

Sample processing

2



Rare cell capture

enriches tumor & immune cells, preserves identity

Cell capture

3



Multi-marker profiling

20+ predictive surface proteins

Imaging & analysis

4



AI-powered insights

therapy response signatures in <1 week

Precision Profiling with CyPhenom™



Identifies actionable targets

Reveals resistant sub-clones

Enables real-time therapy switching

Multiple therapeutic targets with varying expression levels in tumor cells

Milestones

Q3 2023, 2025-2027, 2028-2031

Foundation & Traction | Near-term Validation | Financial Scale & Exit Potential

(Achieved Q3 2023) | **(2025–2027)** | **(2028–2031)**

Core Technology De-Risked

Prototype Chip Built with Proof-of-Concept (Efficient Cell Capture, Sensitive Detection).

IP Secured

Assay & Device/Design Patents Filed.

Key Validation

AI collaboration with Stanford & Top Clinical Advisors Engaged.

2025–2026	2027
Launch initial **CSF** & **FNA Assays**.	Expand to **Immuno-Oncology Phenotyping.**
Initiate **500-sample Clinical Studies.**	Complete **2000 Clinical Samples.**
Secure **Pharma Collaborations.**	Establish **CLIA Lab** (Regulatory) Readiness).



Join Us

$3M Seed Round to Transform Cancer Care



Complete the multi-marker assay and deploy our initial predictive AI model **(using real-patient data)**

Platform



Scale up microfluidic chip manufacturing and **launch clinical pilot** programs with KOLs.

Scale



Secure **3-5 strategic** partnerships with leading pharma companies and academic research labs.

Market



Achieve CLIA/CAP lab validation and submit initial FDA strategy for **therapy-response** applications.

Regulatory

What Makes **CyPhenom™** Unique

Direct surface protein profiling for real-time data

Real-time cell phenotyping

Minimal input, maximal insight

Built for **biologics:** ADCs, CAR-T, immunotherapy

High signal-to-noise with **physical cell isolation**

CyPhenom™ turns discarded samples into life-saving insights.

Exit Strategy

Pharma & Diagnostics

Pharma
Companion diagnostics & trial enrichment

Exit Paths

Diagnostics
Advanced fluid-based oncology diagnostics

Matches patients to ADCs, IOs, CAR-T

- Enables rare-cell, surface marker-based stratification
- Accelerates drug development & CDx value

Timeline
3-6 Years

Genentech (A Member of the Roche Group) · GILEAD · AstraZeneca · MERCK · Bristol Myers Squibb · Pfizer

Comparable Exit
$300 - $600M
(e.g., GRAIL, Foundation)

Fills a gap in non-surgical tumor profiling

- Expands Dx portfolios to LMD, pleural, FNAs
- Proven traction with CLIA + payer path

Timeline
4-6 Years

danaher · Roche · GUARDANT · ThermoFisher SCIENTIFIC · EXACT SCIENCES

Comparable Exit
$150 - $500M
(e.g., Thrive, Haystack, Ignyta)

Built to Deliver in Oncology Diagnostics

Founding Team



Parisa Faghihi, MBA

20+ yrs.

Microfluidics Dev., Business & Operations



Michael C. Dugan, MD

30+ yrs.

Medical & Biotech Clinical Executive



Tony J. Pircher, PhD

25+ yrs.

Oncology Dx/Tx & Patents (>15)



Michael Saghbini, PhD

30+ yrs.

Molecular Products & Patents (>15)

Scientific Advisors

Emma Lundberg Ph.D.
Associate Professor, Bioengineering & Pathology, Stanford University

David Piccioni M.D. Ph.D.
Director, Neuro-Oncology, UCSD

Christopher Bird Ph.D.
CMO at Beckman Coulter DX

Santosh Kesari, M.D. Ph.D.
Neuro-oncologist, Saint John' Cancer Institute & Southern California